Revive Therapeutics (TSE:RVV) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Revive Therapeutics has updated stakeholders on the progress of their lateral flow test kit for detecting long COVID, following guidance from the FDA to pursue a De Novo regulatory pathway, which requires a clinical study for potential approval. As there’s no FDA-approved clinical diagnosis for long COVID yet, the company has secured exclusive rights to novel blood biomarkers for the condition, aiming to address a critical need in post-COVID-19 healthcare.
For further insights into TSE:RVV stock, check out TipRanks’ Stock Analysis page.
